http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 07 Apr 2025 11:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,859,216</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,785,889</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html Mon, 07 Apr 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,859,216</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,785,889</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html Mon, 07 Apr 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,859,216</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,785,889</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html Mon, 07 Apr 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,859,216</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth20 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,785,889</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth80" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+March+31%2C+2025/24607681.html Mon, 07 Apr 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Press+Releases/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html <ul class="bwlistdisc"> <li> All secondary endpoints required to support eyonis™ LCS’ intended use and desired marketing claims achieved in RELIVE </li> <li> eyonis™ LCS previously met primary endpoint, achieving statistically significant superiority compared to state of the art in RELIVE </li> <li> U.S. FDA 510(k) filing is on track for May 2025, and filing for CE marking expected in June 2025 </li> <li> Preparing U.S. commercial launch of eyonis™ LCS in Q4 2025 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT) (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”), </i>manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer http://www.streetinsider.com/Business+Wire/eyonis%E2%84%A2+LCS%2C+Median+Technologies%E2%80%99+AI-Powered+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+Confirmed+Efficacy+and+Safety+in+RELIVE+Pivotal+Study/24572873.html Mon, 31 Mar 2025 12:28:00 -0400 A.06822034 ALMDT O.00990290 O.20026344 http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,757,159</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,695,888</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html Fri, 07 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,757,159</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,695,888</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Press+Releases/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html Fri, 07 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,757,159</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,695,888</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html Fri, 07 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html <p class="bwalignc"> Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations. </p> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies (Paris:ALMDT): </p><table cellspacing="0" class="bwtablemarginb bwblockalignl bwwidth100"> <tr> <td class="bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Total number of shares </p> </td> <td class="bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,757,159</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Number of real voting rights* (excluding treasury shares**) </p> </td> <td class="bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth14 bwalignc" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignc"> <b>18,695,888</b> </p> </td> </tr> <tr> <td class="bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth86" rowspan="1" colspan="1"><p class="bwalignc bwcellpmargin"> Theoretical number of voting rights* http://www.streetinsider.com/Business+Wire/Median+Technologies%3A+Disclosure+of+Total+Number+of+Voting+Rights+and+Number+of+Shares+in+the+Capital+as+of+February+28%2C+2025/24469874.html Fri, 07 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> The shareholders of Median Technologies (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”)</i> are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. </p><p> All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. </p><p> Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise http://www.streetinsider.com/Press+Releases/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html Mon, 03 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> The shareholders of Median Technologies (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”)</i> are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. </p><p> All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. </p><p> Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise http://www.streetinsider.com/Press+Releases/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html Mon, 03 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> The shareholders of Median Technologies (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”)</i> are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. </p><p> All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. </p><p> Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise http://www.streetinsider.com/Business+Wire/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html Mon, 03 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> The shareholders of Median Technologies (<i>FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”)</i> are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. </p><p> All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. </p><p> Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise http://www.streetinsider.com/Business+Wire/Median+Technologies+Announces+the+Availability+of+the+Preparatory+Documents+for+the+Shareholders%E2%80%99+Extraordinary+General+Meeting+on+March+20%2C+2025/24437706.html Mon, 03 Mar 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies <i>(FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”)</i>, a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA. </p><p> Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html Wed, 26 Feb 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies <i>(FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”)</i>, a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA. </p><p> Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html Wed, 26 Feb 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies <i>(FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”)</i>, a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA. </p><p> Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm http://www.streetinsider.com/Business+Wire/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html Wed, 26 Feb 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Business+Wire/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies <i>(FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”)</i>, a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA. </p><p> Fredrik Brag, Median’s CEO and Founder, will present on the Company, latest developments and upcoming milestones on Tuesday, March 4 at 3:10 pm http://www.streetinsider.com/Business+Wire/Median+Technologies+to+Present+at+TD+Cowen%E2%80%99s+45th+Annual+Health+Care+Conference/24407466.html Wed, 26 Feb 2025 11:45:00 -0400 ALMDT O.00990290 http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Showcase+Its+Artificial+Intelligence+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+eyonis%E2%84%A2+LCS%2C+at+the+European+Congress+of+Radiology/24391063.html <ul class="bwlistdisc"> <li> Industry presentation at the AI Theatre: &quot;<i>eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening</i>” </li> <li> Median eyonis™ teams will be at booth #AI-18, AI Exhibition, Expo X1 </li> </ul> <p> SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Median Technologies <i>(</i><i>FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”)</i>, a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of http://www.streetinsider.com/Press+Releases/Median+Technologies+to+Showcase+Its+Artificial+Intelligence+Software+as+a+Medical+Device+for+Lung+Cancer+Screening%2C+eyonis%E2%84%A2+LCS%2C+at+the+European+Congress+of+Radiology/24391063.html Mon, 24 Feb 2025 11:45:00 -0400 ALMDT O.00990290